Safety and efficacy results
| Factors | Different Groups | ||
|---|---|---|---|
| LPBS (n = 25) | FD (n = 22) | P Value | |
| Safety results | |||
| Clinical outcomea | |||
| Good (mRS ≤2) | 14 (56%) | 13 (59.1%) | .831 |
| Poor (mRS 2) | 11 (44%) | 9 (40.9%) | |
| Changes in symptoms | |||
| Nonaggravated | 13 (52%) | 14 (63.6%) | .421 |
| Aggravated | 12 (48%) | 8 (36.4%) | |
| New neurologic deficits due to procedural complications | |||
| Total | 6 (24%) | 9 (40.9%) | .215 |
| Hemorrhagic | 1 (4%) | 2 (9.1%) | .476 |
| Ischemic | 5 (20%) | 9 (40.9%) | .118 |
| Mild-to-severe disability | 6 (24%) | 6 (27.3%) | .861 |
| Neurologic death | 3 (12%) | 2 (9.1%) | .747 |
| Efficacy results | |||
| Angiographic occlusionb | |||
| Complete | 2 (10%) | 7 (41.2%) | .028 |
| Near-complete | 12 (60%) | 7 (41.2%) | .254 |
| Incomplete | 6 (30%) | 3 (17.6%) | .383 |
| Progression of mass effect | |||
| Nonprogressed | 10 (50%) | 12 (70.6%) | .204 |
| Progressed | 10 (50%) | 5 (29.4%) | |
↵a Clinical follow-up data were available for all 47 of the 47 patients included.
↵b Radiologic imaging follow-up data for evaluating angiographic occlusion and progression of mass effect was available for 37 of the 47 patients included, 20 of the 25 patients in LPBS group and 17 of the 22 patients in FD group. Three surviving patients were lost to radiologic imaging follow-up due to poor status.